Is DEA going to reduce manufacturing quotas for oxycodone, the active ingredient in OxyContin ?
All quotas are reviewed annually to ensure that the amount of controlled substances produced are sufficient to meet the legitimate medical, scientific, research, and industrial needs of the U.S. This review includes a yearly forecast of expected changes in medical use, data from prescription and hospital use, as well as abuse, trafficking and diversion data. Quotas may be increased or decreased depending on expected needs or excessive supplies. Excessive inventories of any controlled substance heighten the chances of possible diversion. In the case of oxycodone, the active ingredient in OxyContin , all relevant data is being reviewed.
